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Summary 
Plasminogen activators are membrane-associated, arginine-specific serine proteases which convert the 
inactive plasma zymogen plasminogen to plasmin, an active, broad-spectrum serine protease. Plasmin, the 
major fibrinolytic enzyme in blood, also participates in a number of physiologic functions involving protein 
processing and tissue remodelling, and may play an important role in tumor invasion and metastasis. In HTC 
rat hepatoma cells in tissue culture, glucocorticoids rapidly decrease plasminogen activator (PA) activity. We 
have shown that this decrease is mediated by induction of a soluble inhibitor of PA activity rather than 
modulation of the amount of PA. The hormonally-induced inhibitor is a cellular product which specifically 
inhibits PA but not plasmin. We have isolated variant lines of HTC cells which are selectively resistant to the 
glucocorticoid inhibition of PA but retain other glucocorticoid responses. These variants lack the hormonal- 
ly-induced inhibitor; PA from these variants is fully sensitive to inhibition by inhibitor from steroid-treated 
wild-type cells. Cyclic nucleotides dramatically stimulate PA activity in HTC cells in a time- and concentra- 
tion-dependent manner. Paradoxically, glucocorticoids further enhance this stimulation. Thus glucocorti- 
coids exert two separate and opposite effects on PA activity. The availability of glucocorticoid-resistant 
variant cell lines, together with the unique regulatory interactions of steroids and cyclic 'nucleotides, make 
HTC cells a useful experimental system in which to study the multihormonal regulation of plasminogen 
activator. 
Introduction 
Plasminogen activators (PAs) are membrane- 
associated arginine-specific serine proteases found 
in a variety of tissues (1). PA selectively hydro- 
lyses a single Arg-Val bond of the plasma zymo- 
gen, plasminogen, to yield the active serine pro- 
tease, plasmin, the major fibrinolytic activity in 
blood (2, Fig. 1). Plasmin is a broad-spectrum 
endopeptidase which can act on a variety of pro- 
teins. Because plasminogen is present in plasma in 
relatively high concentrations (I.5 to 2 /~M, or 
0.5% of all plasma proteins), the plasminogen ac- 
tivator-plasmin cascade provides considerable po- 
tential proteolytic activity (2, 3). Thus generation 
of plasmin both amplifies PA activity and broad- 
ens the substrate specificity. In addition to plas- 
min's well-known role in fibrinolysis, it is also in- 
volved in many normal physiologic functions which 
involve protein processing, cell migration and tissue 
remodelling (1,3, 4, Table 1). By acting directly on 
fibrin and directly or indirectly (via activation of 
procollagenase) on connective tissue matrix (5, 6), 
the plasminogen activator-plasmin cascade may al- 
so play an important role in tumor invasion and 
metastasis (l ,  3, 4, 6). 
Not surprisingly for an enzyme of such biological 
importance, plasminogen activator is subject to 
regulation by a variety of effectors (see 7 for re- 
view). Steroid (8-16) and polypeptide hormones 
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Fig, 1. Cartoon representation of plasminogen activation, 
Table 1. Physiological/pathological processes mediated by 
plasminogen activator/plasmin. 
Fibrinolysis 




Migration of  macrophages during inflammation 
Tissue remodelling and destruction 
Rupture of  the ovarian follicle during ovulation 
Implantation of  the mouse embryo 




(17, 18), growth factors (4), cyclic nucleotides (13, 
14, 17-22), retinoids (22-25), lectins (26) and tumor 
promoters (4, 22, 25, 27) are all modulators of PA 
activity in some tissues. Inhibitors of PA and/or  
plasmin are also important regulators of protease 
activities (2, 28-33), and in some experimental sys- 
tems these inhibitors may also be subject to physio- 
logic regulation (10, 11,28, 33). The mechanisms by 
which PA activity is regulated are largely unknown, 
but could involve regulation of the rates of synthe- 
sis or degradation of the PA protein, activation of 
PA itself or of a PA precursor, or regulation of 
specific inhibitors of PA. 
HTC cells are an established line of rat hepatoma 
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cells in long-term tissue culture, which provide a 
favorable experimental system for studying the 
regulation of plasminogen activators. This line is 
extremely well characterized with respect to hor- 
monal regulation of multiple functions, particular- 
ly for the actions of glucocorticoids, insulin, and 
cyclic nucleotides (34-38). Furthermore, it is possi- 
ble to isolate variant HTC cell lines altered in hor- 
monal regulation of various properties, and several 
such lines have been described (9, 39, 40). Over the 
past several years we have exploited these features 
of HTC cells to study the hormonal regulation of 
plasminogen activator and the role of PA in various 
cellular functions modulated by hormones. We 
have described two unique mechanisms of regula- 
tion of PA: first, the glucocorticoid induction of a 
specific inhibitor of plasminogen activator (I0, 1 I, 
28); and second, a paradoxical effect of glucocorti- 
colds on PA regulation in which glucocorticoids 
alone inhibit PA activity but together with cyclic 
nucleotides enhance the dramatic stimulation of 
PA activity by the latter (41). 
tested with either CM or cell extracts of untreated 
HTC cells (as a source of PA) or urokinase (a 
human urinary plasminogen activator) for 20 min 
at 37 °C or 30 min at 25 °C prior to assaying PA 
activity. Inhibitory activity was quantitated by ti- 
trating serial dilutions of CM or cell extracts from 
dexamethasone-treated cells against a fixed amount 
of UK or HTC cell PA. 
Characterization of  plasminogen activator in HTC 
cells 
Multiple molecular weight forms of PA were 
separated by SDS polyacrylamide gel electropho- 
resis under nonreducing conditions. Following 
electrophoresis, SDS was removed from the gels 
and proteins by exchange with the nonionic deter- 
gent Triton X-100, allowing recovery of PA activity 
(45). PA activity was then localized and assayed 
either by elution of PA from homogenized gel slices 
and assay of plasminogen-dependent fibrinolysis, 
by the fibrin-agar underlay method of Granelli-Pi- 
perno & Reich (45), or by plasminogen-dependent 
caseinolytic activity in the gel (46, 47). 
Materials and methods 
Cell culture 
HTC cells were routinely grown in spinner or 
monolayer culture in Minimal Essential Medium 
(Eagle's) without antibiotics, modified to contain 
50 mM tricine, a nonvolatile buffer, 0.5 g/1 sodium 
bicarbonate, and supplemented with 2 mM glutam- 
ine and 5% calf and 5% fetal bovine serum. Experi- 
ments were performed in a chemically-defined me- 
dium identical to the growth medium except that it 
lacked serum and was supplemented with neomycin 
and, where applicable, with 0.1% bovine serum al- 
bumin. 
Assays of  plasminogen activator 
PA was routinely assayed in either conditioned 
medium (CM) or 0.2% Triton X-100 extracts of 
cells using either an 125I-fibrinolytic assay (42) or 
the esterolytic assay (43, 44) developed in this la- 
boratory. HTC cells have no demonstrable plas- 
minogen-independent fibrinolytic, caseinolytie, or 
esterolytic activity. Direct addition of dexametha- 
sone or cyclic nucleotides to the assay mixture has 
no effect on PA activity. Inhibitory activity was 
measured by incubating CM or cell extracts to be 
Enucleation of  HTC cells 
Anucleate HTC cells (cytoplasts) were prepared 
by centrifugation of cells from suspension cultures 
through a discontinuous Ficoll gradient in the pres- 
ence of cytochalasin B. The efficiency of enuclea- 
tion was routinely greater tlaan 92%. Cytoplast 
preparations maintained their membrane integrity 
for at least 24 hours in culture in the absence of 
serum (48). 
Isolation of  variant HTC cells 
An agar-fibrin overlay technique (9, 49) was used 
to identify colonies with plasminogen-dependent 
fibrinolytic activity. Colonies which expressed PA 
activity in the presence of dexamethasone (and 
were thus presumably resistant to the dexametha- 
sone inhibition of PA) were isolated through the 
agar-fibrin overlay and propagated in the absence 
of dexamethasone. Variant cell lines highly resis- 
tant to the dexamethasone inhibition of PA activity 
were obtained after several cycles of such treatment 
(9, 39). 
Materials 
Tissue culture media and sera were obtained 
from Gibco. Dexamethasone was the kind gift of 
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Dr Walter Gall of Merck Laboratories. 8-bromo- 
cAMP was purchased from Boehringer-Mannheim 
and Sigma, and the phosphodiesterase inhibitor, 
1-methyl-3-isobutylxanthine, was obtained from 
Calbiochem-Behring. 12sI-fibrinogen was pur- 
chased from Amersham-Searle and Abbott  Labor- 
atories. Fibrinogen (97% clottable) was obtained 
from Calbiochem-Behring and used without furth- 
er purification. Plasminogen was prepared from 
outdated human plasma by lysine-Sepharose chro- 
matography (50). Urokinase was purchased from 
Collaborative Research or Calbiochem-Behring. 
Plasminogen was iodinated using the lactoperoxi- 
dase method (51). 
Results 
Glueocorticoid regulation of  plasminogen activa- 
tor 
Plasminogen activator activity is found in the 
membrane fraction of HTC cells from which it can 
be released by detergents such as Triton X-100 (10). 
Activity is also found in serum-free medium condi- 
tioned by HTC cells (9, 41, 43). Analysis of PA 
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Fig. 2. Schematic diagram of multiple molecular weight forms of 
HTC cell plasminogen activator. Monolayer cultures of HTC 
cells were incubated for 24 hours in serum-free medium without 
hormones (Lane A), with 0.1/.LM dexamethasone (Lane B), with 
3 mM 8-bromo-cAMP/1 mM MIBX (Lane C), or with 3 mM 
8-bromo-cAMP/1 mM MIBX/0.1 /~M dexamethasone (Lane 
D). Conditioned media were subjected to SDS polyacrylamide 
gel electrophoresis and PA activity was localized on a fibrin-agar 
underlay as described in Materials and methods. Molecular 
weight markers are phosphorylase B (94K), bovine serum al- 













Fig. 3. Time course of dexamethasone inhibition of HTC cell 
plasminogen activator. HTC cells were incubated for the times 
indicated in serum-free medium containing 1 #M dexametha- 
sone. Fibrinolytic activity of cell extracts was measured as de- 
scribed in Materials and methods and was normalized for the 
amount of protein in each sample. Each point represents the 
average of duplicate assays on a single culture. Reproduced from 
reference 10. 
medium on SDS polyacrylamide gels under nonre- 
ducing conditions reveals two major molecular 
weight forms of PA activity of 110 000 and 66 000 
daltons. A minor band of activity is sometimes 
observed at 33 000 daltons (Fig. 2). There does not 
appear to be any difference between the molecular 
weights of the PAs associated with the cell and 
those released into the medium. 
Glucocorticoids rapidly inhibit the activity of PA 
in HTC cells. Inhibition is half-maximal after ap- 
proximately 90 rain and maximal after 4 to 6 hours 
of incubation (Fig. 3). The magnitude of inhibition 
is usually 75 to 100%. Inhibition of PA activity is 
also observed in conditioned medium at later times 
than in cell extracts. Half-maximal inhibition is 
achieved at 5 nM dexamethasone, the same concen- 
tration that half-maximally induces tyrosine ami- 
notransferase and half-maximally inhibits amino 
acid transport in HTC cells; maximal inhibition is 
achieved at 10 to 100 nM dexamethasone (39). 
Dexamethasone could inhibit PA activity by de- 
creasing the amount of PA protein or by decreasing 
its activity (possibly by inducing an inhibitor of this 
protease), or by some combination of these mech- 
anisms. When increasing amounts of an extract of 
dexamethasone-treated cells are mixed with a fixed 
amount  of an extract from control cells (as a source 
of PA activity), there is a concentration-dependent 
inhibition of PA activity, demonstrating that the 
dexamethasone-treated cells contain an inhibitor of 
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Fig. 4. Inhibition of HTC cell plasminogen activator by condi- 
tioned medium from dexamethasone-treated HT C cells. HTC 
cells were incubated for 18 hours with 0.1 #M dexamethasone 
(e) or without hormones (©). Increasing amounts  of conditioned 
medium from these cultures were incubated for 30 rain at 25 °C 
with 10 #g of cell extract from untreated HTC cells (as a source 
of PA) and fibrinolytic activity assayed as described. Each point 
represents the average of duplicate assays. 
PA (10, 11). Cell fractionation experiments have 
demonstrated that the inhibitor is found primarily 
in the soluble 100 000 × g supernatant fraction (10), 
as well as in medium conditioned by dexametha- 
sone-treated cells (Fig. 4). 
An intact nucleus is required for this hormonal 
regulation of PA activity. Cytoplasts prepared by 
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Fig. 5. Inhibition of human  urokinase by conditioned medium 
from dexamethasone-treated HTC cells. HTC cells were incu- 
bated for 18 hours with 0.1 /zM dexamethasone (e) or without 
hormones  (©). Increasing amounts  of conditioned medium were 
incubated for 20 rain at 37 °C with 5 milliPloug units of human  
urokinase and esterolytic activity assayed as described (44). 
Each point represents the average of duplicate assays. 
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centrifugation through Ficoll gradients in the pres- 
ence of cytochalasin B maintain PA activity at lev- 
els comparable to or higher than those of intact 
cells. However, anucleate HTC cells are not respon- 
sive to glucocorticoid regulation of PA activity. 
Dexamethasone does not decrease either intracellu- 
lar or extracellular PA activity of the anucleate 
cells, or induce production of the soluble inhibitor 
of PA activity (52). 
The dexamethasone-induced inhibitor of PA ac- 
tivity (PAl) also inhibits the plasminogen-depen- 
dent fibrinolytic or esterolytic activity of HeLa cells 
(Coleman, unpublished work) and of human uro- 
kinase (Fig. 5), as well as PA from HTC cells. Thus, 
PAI inhibits both major immunochemical types of 
PA, urokinase-like and tissue activator (1). In con- 
trast, plasmin is not inhibited by conditioned medi- 
um from HTC cells incubated with dexamethasone. 
The specificity of the inhibitor for plasminogen 
activation was demonstrated directly by the inhibi- 
tion of urokinase-catalyzed activation of 125I-plas- 
minogen to 125I-plasmin (28). These results show 
that the inhibition is not directed against plasmin, 
but is specific for plasminogen activator. 
Because certain cell types can take up serum pro- 
tease inhibitors from the serum in medium (31,33, 
53) and release them to serum-free medium condi- 
tioned by these cells (3 t), we investigated the origin 
of this hormonally-induced inhibitor in HTC cells. 
SF HTC-H1, a line of cells selected for their ability 
to grow in serum-free medium (54), were grown for 
76 days (at least 30 generations) in the presence or 
absence of serum; dexamethasone induced equiva- 
lent amounts of inhibitory activity in cells grown 
under either condition. Furthermore, the inhibitory 
activity from HTC cells is stable to pH 3 for 2 hours 
at 37 ° C, a treatment which inactivates fibrinolytic 
inhibitors in serum. These results indicate that the 
dexamethasone-induced inhibitor is a cellular pro- 
duct which differs from serum-derived fibrinolytic 
inhibitors (28). 
The inhibitor is inactivated by boiling and bv 
treatment with pepsin under acidic conditions, sug- 
gesting that it is a protein. The PA inhibitory activi- 
ty in CM from dexamethasone-treated cells mi- 
grates as a single band of approximately 45 000 
daltons upon SDS polyacrylamide gel electropho- 
resis under nonreducing conditions (Cwikel & Ge- 
lehrter, unpublished work). PAI is clearly different 
from the 38 000 dalton protease inhibitor, protease 
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nexin, described by Low et al. (32) which inacti- 
vates both thrombin and urokinase. Conditioned 
medium from dexamethasone-treated cells, which 
readily inhibited urokinase, had no effect on 
thrombin activity, even in the presence of heparin 
which accelerates the thrombin-protease nexin in- 
teraction (Coleman & Gelehrter, unpublished 
work). 
We have begun to investigate the interaction of 
PAl with various PAs. Preliminary evidence sug- 
gests that PAl  forms an irreversible covalent com- 
plex with urokinase. In contrast, its interaction 
with PA from HTC ceils can be reversed under 
conditions of SDS polyacrylamide gel electropho- 
resis. Taking advantage of the latter fact, we have 
asked whether dexamethasone decreases PA activi- 
ty directly, in addition to the effects mediated by 
PAI. Cell extracts and CM from dexamethasone- 
treated cells, which have less than 10% of control 
PA activity when assayed by the fibrin plate assay, 
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Figure 6. Schematic diagram of the agar-fibrin overlay tech- 
nique used to isolate variant HTC cell lines resistant to the 
glucocorticoid inhibition of PA. Experimental  details in Mate- 
rials and methods and in references 9 and 39. Reproduced from 
reference 9. 
exhibit PA activity comparable to the controls 
when measured by the fibrin-agar underlay (Fig. 2) 
or by direct assay of gel eluates following SDS 
polyacrylamide gel electrophoresis. These results 
suggest that PA and PAI dissociate during electro- 
phoresis, and that there is no decrease in the 
amount  of PA in cell extracts or medium from 
dexamethasone-treated cells (Cwikel, Coleman, 
Barouski-Miller & Gelehrter, unpublished work). 
Isolation and characterization of  variant hepatoma 
cells resistant to hormonal regulation of  plasmino- 
gen activator 
Utilizing the agar-fibrin overlay technique (Fig. 
6), we have isolated a number of variant HTC cell 
lines which are highly resistant to the dexametha- 
sone inhibition of PA activity (9, 39). These var- 
iants are resistant to a concentration of dexametha- 
sone 1 000 times greater than that necessary to 
completely inhibit PA activity in wild-type ceils 
(39). The nature of the defect in these cells was 
defined by mixing experiments analogous to those 
described above. Dexamethasone-treated variant 
cells show no PAI activity, whereas the PA from 
these cells is fully sensitive to inhibitor from gluco- 
corticoid-treated wild-type cells. Thus the basis of 
hormone resistance in the variants appears to be the 
failure of dexamethasone to induce PAI (10, l 1). 
The growth rate and cloning efficiency of variant 
and wild-type lines, both on plastic and in soft agar, 
are indistinguishable. Morphologically there are no 
consistent differences between the variant and wild- 
type cells. Fluctuation analyses support the hy- 
pothesis that resistance to dexamethasone arises 
randomly and is not induced by the hormone. It 
was not possible to determine the rate at which 
stable variant cells arise, but only to quantitate the 
frequency of the first step in this process. The fre- 
quency with which colonies from a wild-type popu- 
lation form fibrinolytic plaques in the presence of 
dexamethasone is high (approximately 10 -3) and 
this rate is not altered by treatment with two differ- 
ent mutagens: ethylmethane sulfonate and UV 
light. This observation suggests that mutations are 
not the primary cause of resistance in this cell line. 
The karyotypic variability of HTC cells raises the 
possibility that variants might arise from chromo- 
somal segregation events (39). 
Biochemical analysis of the variant cell lines 
demonstrates that they have a lesion specific for the 
regulation of plasminogen activator. The hormonal 
resistance is apparently not due to deficient or de- 
fective steroid receptor function since the variants 
show wild-type induction of tyrosine aminotrans- 
ferase. The lesion in these variants must therefore 
be at some step distal to the entry of the hormone- 
receptor complex into the nucleus. We have also 
shown that 6 of 7 variant cell lines tested show 
wild-type inhibition of amino acid transport by 
glucocorticoids (one variant is partially resistant to 
the inhibitory effect of dexamethasone on trans- 
port). These findings indicate that there is not a 
generalized resistance to all membrane-associated 
dexamethasone responses, but that the cells are 
selectively resistant to the inhibition of PA (39). 
Other variant HTC cell lines which are selectively 
resistant to the dexamethasone induction of tyro- 
sine aminotransferase (40) show wild-type inhibi- 
tion of PA activity by glucocorticoids (55). These 
results indicate that the various glucocorticoid-me- 
diated responses in HTC cells are independently 
rather than coordinately regulated (11, 55). The 
selective resistance of these HTC variants is unique 
and in contrast to the great majority of glucocorti- 
coid-resistant variant cell lines previously described, 
essentially all of which have been shown to have 
deficient or defective glucocorticoid receptors (56, 
57). 
We utilized these variant lines to study the role of 
plasminogen activator in the hormonal regulation 
of other membrane properties. HTC cells exhibit 
increased levels of adhesion to a substrate as well as 
decreased PA activity when incubated with dexa- 
methasone (58). In a variety of cultured cells, adhe- 
sion to a substrate requires specific cell surface 
glycoproteins and intact cytoskeletal elements, and 
there is evidence that plasmin may affect both of 
these components of adhesion (59-61). Using the 
variant HTC cell lines, we tested the hypothesis that 
dexamethasone induces cell adhesion by decreasing 
the activity of PA, which in turn allows the accumu- 
lation of specific cell surface glycoproteins neces- 
sary for adhesion. If this hypothesis were correct 
there should be little or no dexamethasone inhibi- 
tion of adhesion in the variant cell lines. A sensitive 
quantitative assay was developed which measures 
the strength of attachment of radioactively-labeled 
cells to glass scintillation vials following exposure 
to shearing force (62). We found that dexametha- 
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sone induces the adhesiveness of variant HTC cells 
to the same extent as that of wild-type cells. This 
was true when adhesion was measured in serum- 
free medium, in serum-containing medium, or in 
serum-containing medium depleted of, or reconsti- 
tuted with, plasminogen. These results indicated 
that neither PA itself nor plasmin plays a major role 
in cell adhesion in HTC cells and suggested that the 
dexamethasone induction of adhesion might oper- 
ate through the synthesis of cell surface glycopro- 
teins (11,62). 
Cyclic nucleotide regulation of  plasminogen activa- 
tor activity 
Incubation of HTC cells with cAMP deriva- 
tives stimulates cell-associated PA activity 8- to 
20-fold and extracellular PA activity 30- to 1 300- 
fold. This time- and concentration-dependent in- 
crease is enhanced by phosphodiesterase inhibi- 
tors such as l-methyl-3-isobutylxanthine (MIBX). 
Maximal stimulation of PA activity is observed at 
3 mM 8-bromo-cAMP and half-maximal stimula- 
tion at 0.2 mM. A similar concentration depend- 
ence is noted with dibutyryl-cAMP. N6-monobu - 
tyryl-cAMP also stimulated PA activity but cAMP 
itself did not; dibutyryl-cGMP inhibited PA activi- 
ty. Increases in PA activity in cells incubated with 
8-bromo-cAMP are first detectable at 4 hours in 
cell extracts and 6 hours in extracellular medium, 
and are maximal by 8 and 12 hours, respectively 
(Fig. 7). MIBX increases the level of maximal stim- 
ulation, but does not significantly alter the time 
course (41). 
As noted above, dexamethasone decreases PA 
activity by induction of an inhibitor. Paradoxically, 
dexamethasone added simultaneously with cAMP 
derivatives causes a further 4-fold enhancement of 
the cyclic nucleotide stimulation of PA activity 
(41). Analysis of the molecular weight forms of PA 
under these conditions indicates that the same 
110 K and 66 K forms are present in cells treated 
with cyclic nucleotides or cyclic nucleotides plus 
dexamethasone as in control and dexametha- 
sone-treated cells. In addition a minor 33 K dalton 
form of PA is sometimes found in cells incubated 
with cAMP derivatives plus or minus dexametha- 
sone (Fig. 2). Dexamethasone also profoundly al- 
ters the time course of the cyclic nucleotide en- 
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Fig. 7. Time course of 8-bromo-cAMP action in the presence 
and absence of dexamethasone.  HTC cells were incubated for 
0-24 hours  in serum-free medium containing 0.1 #M  dexameth-  
asone (A), 3 mM 8-bromo-cAMP (©), 3 mM 8-bromo-cAMP/  
1 mM MIBX (rq), or 3 mM  8-b romo-cAMP/ l  mM  M1BX/ 
0.1 #M dexamethasone (zx). (e), Control (no additions). Upper 
panel: cell-associated PA activity. Lower panel: extracellular 
PA activity. Inset: expanded ordinate scale to demonstrate  the 
effect of dexamethasone.  In these experiments, the fibrinotytic 
activities of  several different amounts  of each sample were mea- 
sured and the slope of the line (percentage of fibrin solubilized 
per microgram cellular protein or microliter of extracellular 
medium) was determined by linear regression analysis. PA activ- 
ity is expressed as micrograms fibrin solubilized per microgram 
of cellular protein or microliter of extracellular medium. Repro- 
duced from reference 41. 
detected at 4 hours in cells incubated with 8-bromo- 
cAMP and MIBX but not until 12 hours in cells 
incubated with dexamethasone as well (41). Induc- 
tion of inhibitor by dexamethasone might explain 
this delay in appearance of the cyclic nucleotide- 
stimulated increase in PA activity. Glucocorticoids 
thus exert two separate and opposite effects on PA 
activity: induction of an inhibitor and amplification 
of cyclic nucleotide action. Although permissive 
and synergistic effects of dexamethasone on cyclic 
nucleotide action have been reported previously 
(38, 63), glucocorticoid regulation of PA activity is 
unique in that the amplification of cyclic nucleotide 
effects by dexamethasone opposes its regulatory 
action toward a specific enzyme. 
In variant HTC cells selectively resistant to the 
glucocorticoid inhibition of PA activity, dexameth- 
asone still enhances the stimulation of PA activity 
by cyclic nucleotides (Fig. 8). Furthermore, in con- 
trast to its effect in wild-type cells, dexamethasone 
does not alter the time course of 8-bromo-cAMP 
stimulation of PA activity in variant cells; en- 
hancement is first observed at 6 hours and is max- 
imal by 12 hours incubation. These results appear 
to dissociate the glucocorticoid induction of inhibi- 
tor from its enhancement of cyclic nucleotide stim- 
ulation of PA activity. 
The steroid specificity of the glucocorticoid en- 
hancement effect appears to be similar to that for 
glucocorticoid inhibition of PA activity and amino 
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Fig. 8. Time course of 8-bromo-cAMP stimulation of PA activi- 
ty in the presence or absence of dexamethasone in wild-type and 
variant cells. Wild-type and variant HTC cells were incubated 
for 0-24 hours in serum-free medium containing: no additions 
(e), 0.1 ~M dexamethasone ( - ) ,  3 mM 8-bromo-cAMP/1 mM 
MIBX (tq), or 0.1 ~M dexamethasone/3  mM 8-bromo-cAMP/  
1 mM MIBX (z~). Cell-associated PA activity (in 2.5 micrograms 
cellular protein of wild-type cells or 1 microgram cellular protein 
of variant cells) was measured on =2Sl-fibrin plates as described in 
Materials and methods, and expressed as a percentage of total 
radioactivity released. 
acid transport (64), as well as induction of tyrosine 
aminotransferase (65). The optimal inducers, or full 
agonists, dexamethasone and cortisol, show a sim- 
ilar concentration dependence curve for all of these 
phenomena. In each case, dexamethasone was ten 
times more potent than cortisol. The partial ago- 
nists, 11 fl-hydroxyprogesterone and deoxycortico- 
sterone, cause submaximal enhancement of the cyc- 
lic nucleotide stimulation of PA activity and do so 
only at higher steroid concentrations. Tetrahydro- 
cortisol, which does not interact with the glucocor- 
ticoid receptor, fails to enhance cyclic nucleotide 
stimulation of PA activity. The glucocorticoid an- 
tagonist, 17a-methyltestosterone, which has no ef- 
fect on the enhancement of cyclic nucleotide stimu- 
lation by itself, blocks the enhancement by dexa- 
methasone in a concentration-dependent manner. 
These observations suggest that the steroidal en- 
hancement of cyclic nucleotide stimulation of PA 
activity is mediated by the same glucocorticoid re- 
ceptor mechanism which mediates the induction of 
transaminase, and the inhibition of amino acid 
transport and PA activity (7, Barouski-Miller & 
Gelehrter, unpublished work). 
Incubation of HTC cells with cAMP derivatives 
also alters cell morphology, causing cell elongation 
and extension of processes followed by flattening of 
the cells. Plasminogen activator has been reported 
to alter cell morphology in several lines either di- 
rectly (66) or by production of plasmin (67). We 
have shown, however, that the cyclic nucleotide 
effects on cell morphology are not caused by the 
stimulation of PA activity and can be dissociated 
from them. The morphologic changes appear with- 
in 30 to 60 min incubation with cyclic AMP 
derivatives, long before any detectable changes in 
either intracellular or extracellular PA are appar- 
ent. Upon removal of cyclic nucleotides from the 
medium, cell morphology returns to normal within 
two to four hours, a time at which PA activity is 
still significantly elevated. Furthermore, when 
protein synthesis is blocked by cycloheximide, the 
cyclic nucleotide stimulation of PA activity is 
completely blocked; however, induction of mor- 
phologic changes still occurs. Analogous to the si- 
tuation described above for glucocorticoid regula- 
tion of PA and cell adhesion, these results suggest 
independent regulation by cyclic nucleotides of PA 
activity and cell morphology (7, Barouski-Miller & 
Gelehrter, unpublished work). 
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Discussion 
HTC cells provide a useful experimental model 
for studying the hormonal regulation of plasmino- 
gen activator and the role of PA in several cellular 
functions modulated by hormones. In addition to 
various well-characterized hormonal responses in 
these cells, variant cell lines which are resistant to 
specific hormone-mediated functions have been is- 
olated (9, 39, 40, 55, 68). Our studies have revealed 
two unique regulatory mechanisms: glucocorticoids 
inhibit PA activity by inducing a soluble inhibitor 
rather than by regulating the amount of enzyme 
(10, 11, 28); and g!ucocorticoids together with cy- 
clic nucleotides paradoxically enhance the dramat- 
ic stimulation of PA activity by cyclic nucleotides 
(41). 
Further investigation of this system should yield 
interesting information about mechanisms of hor- 
monal regulation of this important protease. The 
ability to study the multiple molecular weight forms 
of PA should allow studies on the hormonal regula- 
tion of the expression of these forms. We can inves- 
tigate whether various hormones Cause differential 
regulation of these forms of plasminogen activator 
and whether they affect intercor~version of these 
forms. The isolation and characterization of the 
dexamethasone-induced inhibitor (PAI) and the 
preparation of specific antibodies to it should allow 
studies on the hormonal regulation of PAI at a 
molecular level. Finally, the paradoxical effects of 
glucocorticoids on PA in this system provide a 
unique opportunity to study the nature of glucocor, 
ticoid-cyclic nucleotide interactions. 
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